Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol for Coronary MRA
NCT05032937Phase 1Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in coronary heart disease (CHD), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: The degree of coronary artery stenosis at 72 hours, Plaque stability of coronary atherosclerotic plaques at 72 hours and 10 more. Started Oct 2021; status: completed.
02
Drugs
ferumoxytol
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT05032937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032937.